

Document downloaded from:

<http://hdl.handle.net/10251/105816>

This paper must be cited as:

García -Laínez, G.; Ana M Marínez-Reig; Limones Herrero, D.; Jiménez Molero, MC.; Miranda Alonso, MÁ.; Andreu Ros, MI. (2018). Photo(geno)toxicity changes associated with hydroxylation of the aromatic chromophores during diclofenac metabolism. *Toxicology and Applied Pharmacology*. 341:51-55. doi:10.1016/j.taap.2018.01.005



The final publication is available at

<https://doi.org/10.1016/j.taap.2018.01.005>

Copyright Elsevier

Additional Information

1 Photo(geno)toxicity Changes Associated with Hydroxylation of
2 the Aromatic Chromophores during Diclofenac Metabolism

3 Guillermo Garcia-Lainez,¹ Ana M. Martínez-Reig,¹ Daniel Limones-Herrero,² M.
4 Consuelo Jiménez,² Miguel A. Miranda*^{1,2} and Inmaculada Andreu*^{1,2}

5 ¹Instituto de Investigación Sanitaria (IIS) La Fe, Hospital Universitari i Politènic La
6 Fe, Avenida de Fernando Abril Martorell 106, 46026 Valencia, Spain

7 ²Instituto de Tecnología Química UPV-CSIC/ Departamento de Química, Universitat
8 Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain

9
10 Corresponding author:

11 Email: Inmaculada Andreu – iandreur@gim.upv.es

12 Miguel A. Miranda – mmiranda@gim.upv.es

13
14
15 Abbreviations: DCF, diclofenac; 5OH-DCF, 5-hydroxy-diclofenac; 4'OH-DCF, 4'-
16 hydroxy-diclofenac; CPZ, chlorpromazine; SDS, sodium dodecyl sulphate; NSAID,
17 nonsteroidal antiinflammatory drug; CYPs, cytochrome P450 enzymes; ssb, single
18 strand break; Fpg, *E. coli* formamidopyrimidine DNA glycosylase; Endo III, *E. coli*
19 endonuclease III; EndoV, T4 endonuclease V; FBS, fetal bovine serum; PBS, phosphate
20 buffered saline; FSK, fibroblasts; DMEM, Dulbecco's modified eagle medium; TAE,
21 tris-acetate-EDTA; NRU, neutral red uptake; PIF, photo-irritation factor.

23 HIGHLIGHTS

24 - Hydroxylation of DCF at the aromatic rings modulates its photo(geno)toxic potential

25 - 5OH-DCF metabolite is phototoxic to cells, as demonstrated by the 3T3 NRU assay

26 - DNA ssb photosensitized by DCF and 5OH-DCF is observed on agarose gel
27 electrophoresis

28 - Comet assay reveals the photodamage induced by DCF and 5OH-DCF to cellular
29 DNA

30 - Most DNA photodamage by DCF and 5OH-DCF is repaired by cells after several
31 hours

32

33

34

35

36

37

38

39

40

41

42

43 **ABSTRACT**

44 Diclofenac (DCF) can cause adverse reactions such as gastrointestinal, renal and
45 cardiovascular disorders; therefore, topical administration may be an attractive
46 alternative to the management of local pain in order to avoid these side effects.
47 However, previous studies have shown that DCF, in combination with sunlight, displays
48 capability to induce photosensitivity disorders. In humans, DCF is biotransformed into
49 hydroxylated metabolites at positions 4' and 5 (4'OH-DCF and 5OH-DCF), and this
50 chemical change produces non negligible alterations of the drug chromophore, resulting
51 in a significant modification of its light-absorbing properties. In this context, 5OH-DCF
52 exhibited higher photo(geno)toxic potential than the parent drug, as shown by several in
53 vitro assays (3T3 NRU phototoxicity, DNA ssb gel electrophoresis and COMET),
54 whereas 4'OH-DCF did not display significant photo(geno)toxicity. This could be
55 associated, at least partially, with the more efficient UV-light absorption by 5OH-DCF
56 metabolite. Interestingly, most of the cellular DNA damage photosensitized by DCF and
57 5OH-DCF was repaired by the cells after several hours, although this effect was not
58 complete in the case of 5OH-DCF.

59

60

61

62

63

64 Keywords: Comet assay, DNA repair capability, Metabolites, Photosensitized DNA
65 damage, Phototoxicity

66 **1. INTRODUCTION**

67 Diclofenac (2-(2,6-dichlorophenylamino)phenylacetic acid, DCF) is a widely prescribed
68 nonsteroidal antiinflammatory drug (NSAID), which can be administered either
69 topically or orally. It is therapeutically used in the treatment of several rheumatic
70 diseases and as an analgesic. As DCF can cause severe adverse reactions such as
71 gastrointestinal, renal and cardiovascular disorders, topical administration may be an
72 attractive alternative to the management of local pain in order to avoid these side
73 effects.¹ However, previous studies have shown that DCF, in combination with sunlight,
74 displays capability to induce photosensitivity reactions.^{2,3,4,5,6}


75 In this context, taking into account that metabolites can generate, upon irradiation,
76 reactive intermediates capable of binding to key biomacromolecules such as DNA,
77 identification of metabolites with phototoxic or adduct forming capability still remains a
78 major challenge. Therefore, although biotransformation is normally associated with a
79 decreased toxicity, metabolites may be more phototoxic and photoreactive than the
80 parent drug.^{7,8,9}

81 Thus, in a previous work we have proven that demethylation of chlorpromazine (CPZ)
82 as a consequence of Phase I biotransformation, does not result in a detoxification but
83 leads to metabolites maintaining identical chromophore to the parent drug and
84 exhibiting an even enhanced phototoxicity.¹⁰

85 In humans, DCF is biotransformed into hydroxylated metabolites *via* oxidation of the
86 aromatic rings by cytochrome P450 enzymes (CYPs).^{11,12} Major metabolic pathways are
87 the hydroxylation in position 4' and 5 (4'OH-DCF and 5OH-DCF, see Figure 1A),
88 which unlike the case of CPZ demethylation are associated with a change in the
89 chromophore. Moreover, as shown in Figure 1B both metabolites 4'OH-DCF and 5OH-

90 DCF display a bathochromic shift of the absorption band towards the UVA region, thus
91 extending the active fraction of solar light able to produce photosensitivity disorders.
92 With this background, the goal of the present work is to assess the photo(geno)toxic
93 potential of DCF metabolites in order to investigate whether DCF biotransformation
94 modulates the potential to photosensitize DNA damage.


95 A)



96

97 B)

98



99

100 **Figure 1.** A) Chemical structures of diclofenac (DCF) and its metabolites 4'OH-DCF
101 and 5OH-DCF. B) Ultraviolet spectra of DCF (red), 4'OH-DCF (blue) and 5OH-DCF
102 (green). Concentrations of DCF and its metabolites were 4×10^{-5} M in PBS.

103 2. MATERIALS AND METHODS

104 2.1 General chemicals and reagents

105 All solvents were commercially available (HPLC grade) and were used without any
106 further purification. Diclofenac sodium salt (**DCF**), 4'-hydroxydiclofenac (**4'OH-DCF**),
107 5-hydroxydiclofenac (**5OH-DCF**) chlorpromazine (CPZ), sodium dodecyl sulphate
108 (SDS), neutral red solution and DNA repair enzymes *E coli* formamidopyrimidine DNA
109 glycosylase (Fpg) and *E coli* endonuclease III (Endo III) were provided by Sigma
110 Aldrich (Madrid, Spain). For the preliminary experiments, 5-hydroxydiclofenac (**5OH-**
111 **DCF**) was synthesized by standard procedures.¹³ Supercoiled plasmid pBR322, DNA
112 repair enzyme T4 endonuclease V (EndoV) and SYBR Safe DNA gel stain were
113 purchased from Roche Diagnostics (Barcelona, Spain), Ecogen (Barcelona, Spain) and
114 Invitrogen (Madrid, Spain), respectively. For cell culture experiments, fetal bovine
115 serum (FBS), Dulbecco's Modified Eagle Medium (DMEM) and penicillin-
116 streptomycin were supplied by Invitrogen (Madrid, Spain) and trypsin-EDTA (0.25%-
117 0.02%) and glutamine (100 mM) solutions were provided by Cultek (Madrid, Spain).
118 Phosphate buffered saline solution (PBS, pH 7.4, 0.01 M) was prepared by dissolving
119 Sigma tablets in the appropriate volume of ultrapure deionized water. Reagent kit for
120 single cell electrophoresis assay was supplied by Trevigen (Barcelona, Spain).

121 2.3 UV Absorption spectra

122 Ultraviolet absorption spectra were recorded on a Shimadzu UV-1800 UV/VIS
123 spectrophotometer. Measurements were performed in PBS (4×10^{-5} M) at room
124 temperature using 1 cm quartz cells with 3.5 mL capacity.

125

126

127 **2.4 Irradiation equipment**

128 The UV light source used in all *in vitro* photosensitization assays was a photoreactor
129 model LZC-4 (Luzchem, Canada) equipped with 14 lamps for top and side irradiation
130 ($\lambda_{\max} = 350$ nm, Gaussian distribution). All irradiations were carried out through the lid
131 of the plates, and in order to avoid overheating ventilation was used and the plates were
132 placed on ice during the irradiation step.

133 **2.5 DNA damage induced by photosensitization**

134 Mixtures containing 200 ng of supercoiled circular plasmid pBR322 and DCF (100 μ M)
135 or its metabolites (100 μ M) were irradiated as described above. Digestion with an
136 excess of the repair enzymes (Fpg, Endo III or Endo V) was performed immediately
137 after UVA irradiation in order to reveal the nature of DNA damages. Upon
138 irradiation/digestion, loading buffer (0.25 % bromophenol blue, 0.25 % xylene cyanol,
139 30 % glycerol in water) was added to each sample. All the samples were loaded on a 0.8
140 % agarose gel containing SYBR® Safe as dye of nucleic acid. Electrophoresis was
141 carried out in Tris-acetate-EDTA (TAE) buffer (0.004 M Tris-acetate, 1 mM EDTA) at
142 100 V for 1 h. Next, the DNA bands were detected under UV light irradiation and
143 visualized using a Gel Logic 200 Imaging System (Kodak). Finally, the relative
144 abundance of supercoiled DNA (Form I) and nicked relaxed DNA (Form II) was
145 quantified by densitometry with the image analyzer Quantity One (Biorad).

146 **2.6 Assessment of cellular photo(geno)toxicity**

147 **2.6.1 In Vitro 3T3 neutral red uptake (NRU) phototoxicity test**

148 BALB/c 3T3 fibroblast cell line was grown in DMEM supplemented with 10% FBS, 4
149 mM glutamine and 1% penicillin/streptomycin and routinely maintained in 75 cm²

150 plastic flasks in a humidified incubator at 37 °C under 5 % CO₂ atmosphere. The 3T3
151 NRU phototoxicity test was performed according to the OECD guideline 432¹⁴ with
152 minor modifications. For each compound two 96-wells plates were seeded at a density
153 of 2.5×10^4 cells/well. Serial dilutions of the test compounds ranging from 4 mM to
154 0.05 mM were added to each plate. After a period of 1h incubation, one plate was
155 irradiated with a dose of UVA equivalent to 5 J/cm² (UVA light), whereas the other
156 plate was kept in a dark box (dark). The viability of UVA-treated control cells in the
157 absence of test compounds was >90% of those kept in the dark indicating the suitability
158 of the UV dose. At the end of the UVA exposure plates were replaced with DMEM
159 medium and then incubated overnight. Next day neutral red solution (50 µg/mL) was
160 added into each well and incubated for 2 h. After that, neutral red medium was
161 discarded, cells were washed with PBS and neutral red extraction was achieved with
162 100 µL of the desorption solution (water 49% (v/v), ethanol 50% (v/v) and acetic acid
163 1% (v/v). The absorbance was recorded at 550 nm on a Multiskan Ex microplate reader.
164 For each compound dose-response curves were developed, which allowed the
165 determination of IC₅₀ values (concentration of compound causing a 50% reduction of
166 the neutral red uptake) in the absence and in the presence of radiation. Finally, the
167 Photo-Irritation-Factor (PIF) was calculated with the following equation: $PIF =$
168 $\frac{IC_{50\text{ DARK}}}{IC_{50\text{ UVA LIGHT}}}$. According to the OECD Guideline¹⁴ a test compound is labeled as
169 “phototoxic” if PIF is >5, “probably phototoxic” if PIF >2 and <5, and “non-
170 phototoxic” when PIF <2. CPZ and SDS were used as positive and negative controls,
171 respectively.

172

173

174 **2.6.2 Nuclear DNA damage by COMET assay**

175 The single cell gel electrophoresis assay, also known as comet assay, was performed as
176 previously described¹⁰ with slight modifications. Human fibroblasts (FSK cell line)
177 were trypsinized, resuspended in cold PBS and placed on ice for 2h. Cells (100000
178 cells/well in two 12-well plates) were seeded and treated with 100 μ M of DCF or its
179 metabolites. CPZ (10 μ M) was used as a positive control. After 1h incubation, one plate
180 was placed in the photoreactor in order to irradiate the cells for 5 min on ice, whereas
181 the other one was kept in a dark box. Next, 100 μ L of each cell suspension were mixed
182 carefully with 100 μ L of 1% low melting point agarose solution and drops were loaded
183 onto Trevigen® treated slides and placed on ice-cold tray to allow its jellification. Then
184 the slides were immersed in coupling jars containing cold lysis buffer (2.5M NaCl, 0.1
185 M Na₂EDTA, 0.01 M Tris, 1% Triton X-100 in distilled water and pH 10) and
186 overnight incubated at 4 °C. In DNA-recovery assays, after drop jellification, the slides
187 were incubated in DMEM medium at 37 °C for different time periods (3h, 6h or 18h)
188 and then subjected to cell lysis. Next day all slides were placed in a Trevigen® Comet
189 assay electrophoresis tank (10 slides per run), covered with 850 mL of cold alkaline
190 electrophoresis buffer (0.2 M NaOH, 1mM EDTA in distilled water and pH \geq 13) and let
191 during 40 min for DNA unwinding at 4 °C. Afterwards, the electrophoresis was run at
192 21 V (\approx 300 mA) for 30 min at 4 °C. When the electrophoresis finished, the slides were
193 neutralized twice in PBS for 5 min and washed once with miliQ water for 5min; DNA
194 was fixed by slide incubation in 70% ethanol for 5 min followed by other 5 min in
195 100% ethanol, and then air-dried. Finally, comet nucleoids and tails were stained by
196 incubating the slides in a SYBR Gold® (1:10000 TE buffer) bath for 30 min, air dried,
197 and kept in darkness until further visualization. For nucleoids and tails DNA
198 visualization a Leica DMI 4000B fluorescence microscope was used and \geq 5 pictures

199 were taken for each sample. Finally, DNA % in tail as a measure of DNA damage was
200 determined for each condition with the analysis of at least 100 DNA comets with the
201 open source analysis software Open Comet 1.3¹⁵

202 **3. RESULTS AND DISCUSSION**

203 **3.1 Phototoxicity**

204 *In vitro* 3T3 NRU phototoxicity assay was performed in order to assess the cell viability
205 upon exposure to DCF and its metabolites in combination with UVA irradiation (5
206 J/cm²). Accordingly, cytotoxicity profiles of BALB/c 3T3 fibroblasts treated with DCF,
207 4'OH-DCF and 5OH-DCF were measured, using neutral red as vital dye, both in dark
208 and in the presence of UVA light. Thus, the IC₅₀ values were determined from dose-
209 response curves for cell viability of cells treated under the conditions described above in
210 the materials and methods section (dose-response curves are provided in Supplementary
211 material, Figure S1).

212 The aim of NRU test is to calculate the PIF that corresponds to the ratio of the IC₅₀
213 under dark or light conditions for each compound. As shown in Table 1, 5OH-DCF
214 metabolite resulted to be potentially phototoxic with a PIF value *ca.* 12, 4 fold more
215 phototoxic than the parent drug. Both DCF and 4'OH-DCF displayed a PIF of 3 and 2,
216 respectively, which can be considered as probable phototoxicity. Table 1 collects the
217 IC₅₀ under dark and UVA light conditions as well as the PIF of all compounds tested.

218 It is known that the photosensitizing properties of DCF are associated with the main
219 photoproduct, which corresponds to a chlorocarbazole derivative, as revealed in
220 photohemolysis and lipid photoperoxidation assays.² Thus, the key process is the
221 photodechlorination, triggered by homolytic carbon-chlorine bond cleavage with
222 generation of a highly reactive aryl radical and chloride anion.¹⁶ Assuming that this
223 reaction occurs in the parent drug as well as in the metabolites under study, the higher

224 phototoxicity of 5OH-DCF could be associated, at least partially, with its more efficient
225 UV-light absorption.

226 **Table 1.** Phototoxicity of DCF and its metabolites in the 3T3 NRU Assay

Compound	IC ₅₀ Dark (μM)	IC ₅₀ UVA Light (μM)	Photoirritant Factor (PIF) ¹
CPZ	84 ± 18	4 ± 1	21
DCF	688 ± 63	254 ± 58	3
4'OH-DCF	766 ± 85	375 ± 55	2
5OH-DCF	813 ± 106	68 ± 27	12
SDS	202 ± 25	244 ± 48	1

227 Data are the mean ± SD of five independent experiments performed in triplicate. CPZ
228 and SDS were used as positive and negative controls of phototoxicity respectively.
229


230 ¹According to the OECD 432 Guide (2004), PIF < 2 predicts “no phototoxicity”,
231 2 < PIF < 5 predicts “probable phototoxicity” and PIF > 5 predicts “phototoxicity”.

232 233 **3.2 Photogenotoxicity of DCF and its metabolites**

234 Irradiations of DCF, 4'OH-DCF and 5OH-DCF in the presence of supercoiled circular
235 DNA (pBR322) were performed using a multilamp photoreactor ($\lambda_{\text{max}} = 355 \text{ nm}$) in
236 order to detect DNA damage. Quantification by densitometry of the conversion of
237 native supercoiled form I into circular form II (Figure 2A) shown in agarose gel (Figure
238 2B) evidenced single strand break (ssb) formation. It is interesting to note that 5OH-
239 DCF exhibited higher photogenotoxic potential than the parent drug whereas 4'OH-
240 DCF did not display significant photogenotoxicity (Figure 2).

241 Moreover, in order to reveal the nature of damages induced on the DNA bases, different
242 DNA-repair enzymes were used: i) T4 endonuclease V (Endo V) for cyclobutane


243 thymine dimers (CPDs), ii) endonuclease III (Endo III) for degradation products of
 244 pyrimidine bases and iii) formamidopyrimidine DNA glycosylase (FPG) for oxidized
 245 purines. Thus, ssb formation was enhanced for 5OH-DCF metabolite (data reported in
 246 Supplementary material, Figure S2) in all cases.



247

248 **Figure 2.** A) Induction of single strand brakes (ssb) in supercoiled circular pBR322
 249 plasmid (200 ng/ μ L) alone (negative control, NC) or treated with DCF and its
 250 metabolites at 100 μ M upon 30 minutes UVA irradiation (\square) or not (\blacksquare) using a
 251 multilamp photoreactor $\lambda_{\text{max}} = 350$ nm. DNA Form II was quantified by densitometry of
 252 agarose gel electrophoresis. Data represent the mean \pm SD of four independent
 253 experiments and asterisks indicate significant differences relative to the formation of
 254 DNA Form II in Dark conditions by the T-Student test (** $p < 0.01$). B) Agarose gel
 255 electrophoresis of plasmid pBR322 alone (NC) or in the presence of 5OH-DCF, in the
 256 dark (-) or upon 5 minutes UVA irradiation (+). Ketoprofen was used as positive control
 257 (PC).

258 Assessment of cellular photogenotoxicity was performed by Comet assay under alkaline
259 conditions to reveal the combined nuclear DNA damage resulting from single-strand
260 breaks, double-strand breaks and alkali-labile sites. For this purpose, human fibroblasts
261 (FSK) were embedded in agarose on a slide and incubated for 1 h with DCF and its
262 hydroxylated metabolites. Next, alkaline electrophoresis was carried out after 5 min of
263 UVA exposure (2 J/cm^2) and subsequent lysis. In the course of electrophoresis, the
264 damaged and fragmented DNA migrates away from the nucleus and upon staining with
265 SYBR Gold the fluorescence of the nuclei was observed. Percentage of DNA damage
266 was calculated by means of OpenComet software.



267

268

269 **Figure 3.** Alkaline comet assay and DNA repair capability of FSK cells treated with
270 DCF and its metabolites. A) Percentage of DNA damage calculated by OpenComet
271 software of untreated FSK cells (Negative control, NC) or treated with DCF and its
272 metabolites (100 μ M). Cells were left unexposed (Dark, ■), irradiated for 5 minutes
273 (UVA Light, □) or irradiated for 5 minutes followed by 6 h of cell recovery (UVA Light
274 + Time recovery 6h, ■), respectively. Data are the mean \pm SD of three independent
275 experiments. Asterisks indicate significant differences relative to the untreated FSK
276 cells in dark conditions by the T-Student test (* p <0.05; ** p <0.01; *** p <0.001). B)
277 Fluorescence microscopy images of DCF and 5OH-DCF Comet assay experiments.

278 As shown in Figure 3, 5OH-DCF showed again higher photogenotoxicity than the
279 parent drug DCF and 4'OH-DCF metabolite (see Supplementary material, Figure S3).
280 Moreover, another set of experiments were performed in order to investigate the ability
281 of FSK cells to repair nuclear DNA damage generated by DCF and metabolites in
282 combination with UVA light. For this purpose, FSK cells treated (with drug and
283 metabolites) and irradiated were incubated for different time periods (3h, 6h and 18h)
284 and the remaining DNA damage was calculated as described above. As a general trend
285 DNA damage decreased with the time of recovery. Interestingly, for DCF it was shown
286 that most DNA damage was repaired within 3h after irradiation whereas for 5OH-DCF
287 a significant residual DNA damage (around 25%) was still present even after 18 h of
288 cell recovery (Figure 3 and Supplementary material, Figure S4).

289 **4. CONCLUSION**

290 Hydroxylation of the aromatic rings at positions 4' and 5 occurs during phase I
291 biotransformation of DCF. This chemical change produces non negligible alterations of
292 the drug chromophore and results in a significant modification of its light-absorbing

293 properties. Accordingly, the phototoxic and photogenotoxic potential of DCF, 4'OH-
294 DCF and 5OH-DCF are expectedly different, as indicated by 3T3 NRU phototoxicity
295 assay, the DNA single strand break gel electrophoresis assay and the COMET assay.
296 The most remarkable result is the enhanced photo(geno)toxicity of 5OH-DCF, which
297 was consistently observed in all experiments. Interestingly, most of the cellular DNA
298 damage photosensitized by DCF and 5OH-DCF was repaired by the cells after several
299 hours, although this effect was not complete in the case of 5OH-DCF.

300

301 **ACKNOWLEDGEMENTS**

302 We would like to thank M. Dolores Coloma for technical assistance in the preliminary
303 experiments.

304

305 **FUNDING**

306 This work was supported by the Carlos III Institute of Health (Grants: RD16/0006/0030,
307 PI16/01877)), by the MINECO (Grant: CTQ2013-47872), and by the Generalitat
308 Valenciana (Prometeo II/2013/005).

309 **REFERENCES**

¹ Merk, H. F. (2007). "Topical diclofenac in the treatment of actinic keratoses" *Int. J. Dermatol.* **46**, 21.

² Encinas, S.; Bosca, F.; Miranda, M. A. (1998). "Phototoxicity Associated with Diclofenac: A Photophysical, Photochemical, and Photobiological Study on the Drug and Its Photoproducts" *Chem. Res. Toxicol.* **11**, 946.

³ Lhiaubet-Vallet, V.; Miranda, M. A. "Photosensitization by drugs", in *CRC Handbook Organic Photochemistry Photobiology 2012*, 1541.

⁴ Akat, P. B (2013). "Severe photosensitivity reaction induced by topical diclofenac" *Indian J. Pharmacol.* **45**, 408.

⁵ Fernandez-Jorge, B.; Goday-Bujan, J. J; Murga, M.; Piñeyro Molina, F.; Perez-Varela L.; Fonseca, E. (2009) "Photoallergic contact dermatitis due to diclofenac with cross-reaction to aceclofenac: two case reports" *Contact Derm.* **61**, 236.

-
- ⁶ Al-Kathiri, L.; Al-Asmaili A. (2016) “Diclofenac-Induced Photo-Onycholysis” *Oman Med. J.* **31**, 65.
- ⁷ Kato, M.; Ohtake, H.; Sato, H.; Seto, Y.; Onoue, S. (2017) “Enzymatic reactive oxygen species assay to evaluate phototoxic risk of metabolites” *Toxicol. Lett.* **278**, 59.
- ⁸ Pearson, P. G. and L. C. Wienkers (2009). Handbook of Drug Metabolism, 2nd Ed.
- ⁹ Miranda, M. A.(1997) “Phototoxicity of drugs”, in *In vitro methods in pharmaceutical research* (Castell, J. V., and Gomez-Lechon, M. J., Eds.), pp 289-315, Academic Press, San Diego.
- ¹⁰ Palumbo, F.; Garcia-Lainez, G.; Limones-Herrero, D.; Coloma, M.D.; Escobar, J.; Jiménez, M.C.; Miranda, M.A.; Andreu, I. (2016) “Enhanced photo(geno)toxicity of demethylated chlorpromazine metabolites”. *Toxicol. Appl. Pharmacol.* **313**, 131.
- ¹¹ Kenny, J. R.; Maggs, J. L.; Meng, X.; Sinnott, D.; Clarke, S. E.; Park, B. K.; Stachulski, A. V. (2004) “Syntheses and Characterization of the Acyl Glucuronide and Hydroxy Metabolites of Diclofenac” *J. Med. Chem.* **47**, 2816.
- ¹² Stierlin, H.; Faigle, J.W.; Sallmann, A., Kung, W., Richter, W.J., Kriemler, H.P., Alt, K.O., Winkler, T. (1979). “Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites”. *Xenobiotica* **9**, 601.
- ¹³ Othman, S.; Mansuy-Mouries, V.; Bensoussan, C.; Battioni, P.; Mansuy, D. C. R. (2000) *Acad. Sci. Paris, Série IIC, Chimie/Chemistry*, **3**, 751.
- ¹⁴ OECD (2004). OECD Guidelines for the Testing of Chemicals Test No. 432: In Vitro 3T3 NRU Phototoxicity Test (Original Guideline, adopted 13th April 2004)
- ¹⁵ Gyori, B. M., Venkatachalam, G., Thiagarajan, P. S., Hsu, D. & Clement, M. (2014). “OpenComet : An automated tool for comet assay image analysis”. *Redox Biol.* **2**, 457.
- ¹⁶ Encinas, S.; Bosca, F.; Miranda, M. A. (1998) “Photochemistry of 2,6-dichlorodiphenylamine and 1-chlorocarbazole, the photoactive chromophores of diclofenac, meclofenamic acid and their major photoproducts” *Photochem. Photobiol.* **68**, 640.